title: Kidney function in very low birth weight infants with furosemide-related renal calcifications at ages 1 to 2 years.
abstract: To determine whether long-term renal sequelae follow the use of furosemide in preterm infants, we evaluated renal function in 27 former very low birth weight infants (less than 1500 gm) at 1 to 2 years of age. Patients were classified into three groups on the basis of status at the time of discharge from the hospital: group 1 (n = 7) had no furosemide treatment or renal calcifications, group 2 (n = 10) had furosemide therapy but no calcifications, and group 3 (n = 10) had furosemide therapy with renal calcifications. Renal ultrasonography at the time of the study demonstrated resolution of the calcifications in six patients in group 3. No differences in renal function were observed between groups 1 and 2. Creatinine clearance (mean +/- SEM) in group 3 (83.6 +/- 7.8 ml/min per 1.73 m2) was significantly lower than clearance in groups 1 and 2 (103.2 +/- 6.5 and 109.1 +/- 5.1, respectively; p less than 0.05). Children in group 3 had significantly higher urinary calcium/creatinine ratios and fractional excretion of sodium and lower tubular reabsorption of phosphate than children in the two other groups had. Urine-blood difference in carbon dioxide tension after oral acetazolamide load, which indicates the ability of the distal tubule to secrete hydrogen ions, was 8.4 +/- 3.4 mm Hg in group 3, significantly lower than values in groups 1 and 2 (22.6 +/- 3.1 and 28.0 +/- 4.3 mm Hg, respectively, p less than 0.05). Within group 3 the four children with persistent renal calcifications had significantly lower urine-blood carbon dioxide tension differences than did those with resolution of calcifications (p = 0.02). We conclude that furosemide-related renal calcifications in very low birth weight infants may lead to glomerular and tubular dysfunction; further long-term follow-up of this population is recommended.
authors.affiliation: Department of Pediatrics, Children's Mercy Hospital, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri.
authors.forename: G J
authors.initials: GJ
authors.lastname: Downing
authors.forename: J C
authors.initials: JC
authors.lastname: Egelhoff
authors.forename: D K
authors.initials: DK
authors.lastname: Daily
authors.forename: M K
authors.initials: MK
authors.lastname: Thomas
authors.forename: U
authors.initials: U
authors.lastname: Alon
mesh_terms: D000042:Absorption; D002114:Calcinosis / Q000139:chemically induced* / Q000150:complications / Q000378:metabolism; D002118:Calcium / Q000652:urine; D002245:Carbon Dioxide / Q000097:blood / Q000652:urine; D003404:Creatinine / Q000652:urine; D005260:Female; D005665:Furosemide / Q000009:adverse effects*; D006801:Humans; D007223:Infant; D007230:Infant, Low Birth Weight / Q000502:physiology*; D007231:Infant, Newborn; D007674:Kidney Diseases / Q000139:chemically induced* / Q000150:complications / Q000503:physiopathology*; D007677:Kidney Function Tests; D008297:Male; D009397:Nephrocalcinosis / Q000150:complications; D010710:Phosphates / Q000493:pharmacokinetics; D011446:Prospective Studies; D012964:Sodium / Q000652:urine
chemical_list: D010710:Phosphates; D002245:Carbon Dioxide; D005665:Furosemide; D012964:Sodium; D003404:Creatinine; D002118:Calcium